Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.60 -0.11 (-0.43%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
360 Stocks in the S&P 500 Underperformed the Benchmark's 2024 Gain of 24%. Here's 2 High-Yielding S&P 500 Stocks to Buy in 2025, According to Wall Street.
Via The Motley Fool
Topics Stocks
Exposures US Equities
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
Via The Motley Fool
10 Overlooked Stocks Set to Soar in 2025
All 10 underperformed in 2024, but I believe they'll turn things around in 2025. 
Via The Motley Fool
Stocks Going Ex Dividend In January 2025
The following is a short list of some of the many stocks going ex-dividend during the next month. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Better Income Stock: Pfizer or Altria Group?
Via The Motley Fool
This Is What Whales Are Betting On Pfizer
Via Benzinga
From Uncertainty to Strength: Navigating Life with Cervical Cancer
(BPT) - Sponsored by Pfizer Inc. and Genmab A/S 
Via Brandpoint
4 Dividend Stocks to Double Up on Right Now
Via The Motley Fool
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025. 
Via Benzinga
Got $500? This Top Dividend ETF Is a Great Buy After Its Recent Sell-Off.
Via The Motley Fool
Topics ETFs
Stocking Stuffers for Income Investors: 3 Ultra-High-Yield Dividend Stocks to Buy Before the End of 2024
Via The Motley Fool
Pfizer: Guidance Reaffirmed, Nice Yield. What's Not To Like?
Pfizer Inc. recently released its full-year 2025 guidance and reaffirmed its 2024 outlook, aligning with Street expectations. It seems having faith in the company may have paid off. 
Via Talk Markets
Topics Stocks / Equities
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool
The Stock Market Is Historically Pricey: Here's How I'm Positioning My Portfolio for 2025
When things seem too good to be true on Wall Street, they usually are. 
Via The Motley Fool
My Top 10 Stocks to Buy for 2025
Via The Motley Fool
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
Via The Motley Fool
Pfizer Sparks Analyst Cheer With 2025 Guidance: Retail Maintains Extremely Bullish Stance
Some analysts are optimistic about Pfizer’s potential for growth, especially considering its focus on oncology and recent strategic acquisitions. 
Via Stocktwits
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
Via Investor's Business Daily
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
3 of the Safest Ultra-High-Yield Dividend Stocks to Buy in 2025
These top-tier income stocks are sporting an average yield of 8.53%! 
Via The Motley Fool
What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?
Shares of Pharmacy-benefit managers (PBMs) including CVS Health Corp (NYSE:CVS), UnitedHealth Group Inc (NYSE:UNH) and Cigna Group (NYSE:CI) are moving lower Tuesday on continued downside pressure... 
Via Benzinga
Topics Government
Exposures Political
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
Shares of Pfizer (PFE) are trading higher after the company affirmed its guidance. They are currently testing resistance. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback